Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Invested Capital (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Invested Capital for 7 consecutive years, with $890.2 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 31.81% to $890.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $890.2 million through Dec 2025, up 31.81% year-over-year, with the annual reading at $890.2 million for FY2025, 31.81% up from the prior year.
  • Invested Capital hit $890.2 million in Q4 2025 for Harmony Biosciences Holdings, up from $855.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $890.2 million in Q4 2025 to a low of $154.0 million in Q3 2021.
  • Historically, Invested Capital has averaged $488.2 million across 5 years, with a median of $489.1 million in 2023.
  • Biggest YoY gain for Invested Capital was 167.56% in 2021; the steepest drop was 47.71% in 2021.
  • Year by year, Invested Capital stood at $188.5 million in 2021, then soared by 114.76% to $404.8 million in 2022, then rose by 19.06% to $482.0 million in 2023, then surged by 40.13% to $675.4 million in 2024, then soared by 31.81% to $890.2 million in 2025.
  • Business Quant data shows Invested Capital for HRMY at $890.2 million in Q4 2025, $855.1 million in Q3 2025, and $791.8 million in Q2 2025.